Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

For an article about how weight-loss drugs affect marriage and intimacy ... who has lost 60 pounds on Zepbound, described how it felt to be out in public as a couple when she was in a bigger ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

During your appointment, the healthcare professional reviews your medical history, discusses any health concerns, and assesses your weight loss goals to determine whether Zepbound suits you.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Under medical supervision, GLP-1 agonists often lead to safe, sustainable weight loss, as noted in clinical reviews ... for a full list of side effects. Zepbound is a GLP-1 agonist containing ...